An arbitrator issued a decision on Friday in a dispute between Japan-based pharmaceutical company Daiichi Sankyo Company, Ltd. And American biotechnology company Seagen, Inc., denying all claims made by Seagen.
Specifically, Daiichi Sankyo retains all patent rights to its antibody drug conjugate (ADC) technology and will continue to develop and commercialise these medicines as planned. In November 2019, Daiichi Sankyo filed a Declaratory Judgment action in the District Court of Delaware against Seagen in response to communications from Seagen claiming certain intellectual property rights related to Daiichi Sankyo's ADC technology. Seagen's claims related to a collaboration agreement between the two companies from 2008 to 2015. In response, Seagen filed an arbitration demand in connection with the dispute with the American Arbitration Association in the same month, resulting in an arbitration and Friday's decision.
'We are extremely pleased that, based on the facts of this matter, the arbitrator recognised that Daiichi Sankyo retains ownership of all patents at issue in the arbitration and that our platform ADC technology was developed by Daiichi Sankyo,' said Sunao Manabe, Daiichi Sankyo, Company, Ltd president and CEO. 'Daiichi Sankyo is proud of our legacy and strength in innovative science and technology and remains committed to bringing our ADCs to patients who need new standards of care in cancer treatment.'
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886